Phenotypic transformation as a cause of secondary drug resistance to osimetinib clinical observation

by L. A. Nelyubina, E. V. Reutova, K. K. Laktionov, D. I. Yudin, D. T. Marinov, E. N. Kozak, V. V. Mochalnikova
Published 2018-11-01

New possibilities in the treatment of EGFR mutation-positive non-small-cell lung cancer patients after the progression on a 1st and 2nd generation EGFR tyrosine kinase inhibitors

by K K Laktionov, E V Reutova, L A Nelyubina, M Yu Pitkevich, M A Okruzhnova, M S Ardzinba, D I Yudin, I A Demidova, A R Zaretsky
Published 2018-06-01